Key result
Early inclisiran post-ACS achieves guideline LDL-C targets in 100% of patients at 30 days.
Why the study?
Does inclisiran added to standard therapy rapidly reduce LDL-C levels in patients early after acute coronary syndrome?
Cohort (n=16)
No
Does inclisiran added to standard therapy rapidly reduce LDL-C levels in patients early after acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Inclisiran added to standard therapy early after ACS safely and rapidly reduces LDL-C to guideline-recommended levels within 30 days.
Elevated low-density lipoprotein cholesterol (LDL-C) after acute coronary syndrome (ACS) significantly increases cardiovascular risk. Timely reduction of LDL-C is crucial, but it takes several weeks to achieve optimal LDL-C levels with standard therapy. Monoclonal antibodies that inhibit PCSK9 have been demonstrated in some small randomised trials to rapidly abate LDL-C levels when used early after hospital admission for ACS. Inclisiran, a PCSK9-inhibiting siRNA, has recently been introduced into clinical practice; however, no information is available about its effectiveness and safety as a fast-track lipid-lowering agent in this clinical context. We conducted a prospective, real-world study evaluating a fast-track lipid-lowering approach starting inclisiran on top of standard therapy in 16 consecutive ACS patients admitted to our cardiac intensive care unit with a high baseline LDL-C level (147.2 ± 35.7 mg/dL). Patients started inclisiran as add-on therapy as soon as baseline LDL-C levels were available. We assessed LDL-C levels and the mean change of LDL-C at baseline, discharge, 15-day and 30-day follow-up. Inclisiran, added to standard therapy, reduced LDL-C levels to 30.3 ± 13.0 mg/dL at 30-day follow-up. The guideline-recommended LDL-C levels (≤55 mg/dL, ≥50 % reduction) were achieved in 73.3 % of patients at 15 days and in 100 % of patients at 30 days, with no adverse effects. This pilot study shows promise for inclisiran as a novel therapeutic option to improve cardiovascular outcomes in patients with ACS by contributing to achieving an early and sustained reduction in LDL-C levels. Graphical abstract illustrating the study design, patient enrolment process, and primary study findings. • Elevated LDL after acute coronary syndrome (ACS) raises cardiovascular risk. • PCSK9 inhibitors on top of standard anti-lipid treatment contribute to lowering LDL rapidly to guidelines-recommended levels. • Inclisiran, taken within one month of ACS hospitalisation, was safe. • This study suggests that inclisiran should be further studied as a valuable addition to early ACS management.
No takes yet. Share an insight, caveat, or question.
Lupi et al. (2025) conducted a cohort in Acute coronary syndrome (n=16). Inclisiran on top of standard therapy was evaluated on Achievement of guideline-recommended LDL-C levels (≤55 mg/dL, ≥50 % reduction) at 30 days. Inclisiran added to standard therapy early after acute coronary syndrome achieved guideline-recommended LDL-C levels in 100% of patients at 30 days, with no adverse effects.
Synapse has enriched 10 related papers. Consider them for comparative context: